DANICOPAN - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for danicopan and what is the scope of freedom to operate?
Danicopan
is the generic ingredient in one branded drug marketed by Alexion Pharms Inc and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.Danicopan has one hundred and four patent family members in twenty-four countries.
One supplier is listed for this compound.
Summary for DANICOPAN
| International Patents: | 104 |
| US Patents: | 1 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 24 |
| Patent Applications: | 40 |
| What excipients (inactive ingredients) are in DANICOPAN? | DANICOPAN excipients list |
| DailyMed Link: | DANICOPAN at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for DANICOPAN
Generic Entry Date for DANICOPAN*:
Constraining patent/regulatory exclusivity:
TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for DANICOPAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Alexion Pharmaceuticals | Phase 3 |
| Celerion | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for DANICOPAN
US Patents and Regulatory Information for DANICOPAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alexion Pharms Inc | VOYDEYA | danicopan | TABLET;ORAL | 218037-001 | Mar 29, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alexion Pharms Inc | VOYDEYA | danicopan | TABLET;ORAL | 218037-002 | Mar 29, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alexion Pharms Inc | VOYDEYA | danicopan | TABLET;ORAL | 218037-001 | Mar 29, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alexion Pharms Inc | VOYDEYA | danicopan | TABLET;ORAL | 218037-001 | Mar 29, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Alexion Pharms Inc | VOYDEYA | danicopan | TABLET;ORAL | 218037-002 | Mar 29, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for DANICOPAN
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2015130838 | ⤷ Sign Up | |
| Japan | 2017508789 | 補体媒介障害の治療のための化合物 | ⤷ Sign Up |
| Canada | 2940769 | COMPOSES AMINES POUR TRAITER LES TROUBLES A MEDIATION PAR LE COMPLEMENT (AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS) | ⤷ Sign Up |
| Canada | 2940774 | COMPOSES D'ETHER POUR LE TRAITEMENT DE TROUBLES DANS LEQUEL INTERVIENT LE COMPLEMENT (ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS) | ⤷ Sign Up |
| Eurasian Patent Organization | 038607 | АРИЛЬНЫЕ, ГЕТЕРОАРИЛЬНЫЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ОПОСРЕДОВАННЫХ КОМПЛЕМЕНТОМ РАССТРОЙСТВ (ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATING COMPLEMENT-MEDIATED DISORDERS) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
